Press coverage about Caladrius Biosciences (NASDAQ:CLBS) has trended somewhat positive on Sunday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Caladrius Biosciences earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.2479324291543 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Caladrius Biosciences (CLBS) traded up $0.28 during mid-day trading on Friday, hitting $3.70. 121,542 shares of the company were exchanged, compared to its average volume of 64,784. Caladrius Biosciences has a 1-year low of $2.63 and a 1-year high of $7.79.

Caladrius Biosciences (NASDAQ:CLBS) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 96.80%. analysts expect that Caladrius Biosciences will post -2.33 earnings per share for the current year.

CLBS has been the topic of a number of analyst reports. ValuEngine raised shares of Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research raised shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Tuesday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Caladrius Biosciences in a report on Friday, November 10th.

TRADEMARK VIOLATION WARNING: “Caladrius Biosciences (CLBS) Receives News Impact Score of 0.13” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.watchlistnews.com/caladrius-biosciences-clbs-receives-news-impact-score-of-0-13/1756205.html.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.

Insider Buying and Selling by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Receive News & Ratings for Caladrius Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.